TY - JOUR
T1 - Essential Fatty Acid Deficiency with SMOFlipid Reduction in an Infant with Intestinal Failure–Associated Liver Disease
AU - Memon, Naureen
AU - Hussein, Karen
AU - Hegyi, Thomas
AU - Herdt, Aimee
AU - Griffin, Ian J.
N1 - Funding Information: N. Memon, K. Hussein, and T. Hegyi equally contributed to the conception and design of the research; N. Memon, K. Hussein, and T. Hegyi contributed to the acquisition of the data; N. Memon, A. Herdt, and I. J. Griffin contributed to the analysis and interpretation of the data; N. Memon drafted the manuscript; and all authors critically revised the manuscript, agree to be fully accountable for ensuring the integrity and accuracy of the work, and read and approved the final manuscript.
PY - 2019/3
Y1 - 2019/3
N2 - Multicomponent lipid emulsions, such as SMOFlipid, contain intermediate amounts of essential fatty acids (EFAs) compared with traditional soybean–oil based lipid emulsions and 100% fish–oil lipid emulsions. We describe the development of moderate EFA deficiency (EFAD) and slow weight gain in an infant with intestinal failure–associated liver disease managed with SMOFlipid reduction (1 g/kg/d). Once SMOFlipid dosage was increased (2–3 g/kg/d), EFA levels normalized, adequate growth resumed, and the infant's cholestasis resolved. We recommend avoiding lipid reduction of SMOFlipid, which not only increases the risk for EFAD, but also is unnecessary given that cholestasis can be reversed on conventional doses of SMOFlipid.
AB - Multicomponent lipid emulsions, such as SMOFlipid, contain intermediate amounts of essential fatty acids (EFAs) compared with traditional soybean–oil based lipid emulsions and 100% fish–oil lipid emulsions. We describe the development of moderate EFA deficiency (EFAD) and slow weight gain in an infant with intestinal failure–associated liver disease managed with SMOFlipid reduction (1 g/kg/d). Once SMOFlipid dosage was increased (2–3 g/kg/d), EFA levels normalized, adequate growth resumed, and the infant's cholestasis resolved. We recommend avoiding lipid reduction of SMOFlipid, which not only increases the risk for EFAD, but also is unnecessary given that cholestasis can be reversed on conventional doses of SMOFlipid.
UR - http://www.scopus.com/inward/record.url?scp=85052638289&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052638289&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/jpen.1432
DO - https://doi.org/10.1002/jpen.1432
M3 - Article
C2 - 30088831
SN - 0148-6071
VL - 43
SP - 438
EP - 441
JO - Journal of Parenteral and Enteral Nutrition
JF - Journal of Parenteral and Enteral Nutrition
IS - 3
ER -